# US 2015/0104440 A1 · MiRNA-31 AS A DIAGNOSTIC, PROGNOSTIC AND THERAPEUTIC AGENT IN CANCER

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0104440 A1
- Document ID: US20150104440A1
- Status: Published application
- Kind: A1
- Application number: 14/381,394
- Filed: 2013-04-12
- Published: 2015-04-16
- Earliest claimed: 2012-04-12
- Assignees: Cornell University
- Applicants: Cornell University
- Inventors: Pei-Chun Lin; Mark A. Rubin
- Web page: https://patentgrep.com/patent/US20150104440A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- A61P 13/08: of the prostate
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 2310/141: MicroRNAs, miRNAs
- C12Q 2600/154: Methylation markers
- C12Q 2600/158: Expression markers
- C12Q 2600/178: miRNA, siRNA or ncRNA
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The current disclosure reveals a complex regulatory pattern between miR-31 and AR, indicating that miR-31 plays a key role in prostate cancer development and progression. Another aspect of the current disclosure shows that miR-31 directly targets and destabilizes AR mRNA through interaction with the AR mRNA coding sequence showing that miR-31, or a fragment thereof has the ability to act as a novel therapeutic agent in treating cancer. The current disclosure also shows that AR indirectly represses miR-31 expression by binding to the miR-31 promoter region and modulating methyltransferase activity. Another aspect of the current disclosure shows that miR-31 indirectly modulates AR activity by modulating regulators of cell cycle progression. The disclosure further provides an isolated nucleic acid that modulates the activity of the androgen receptor in a cell. The disclosure further provides a method of treating a prostate cancer in a subject, by administering to the subject an effective amount of an agent that modulates the activity or levels of miR-31.

## Claims

### Claim 1

A method of diagnosing prostate cancer in a subject comprising
(a) obtaining a biological sample from said subject, and
(b) measuring the level of miR-31 promoter methylation in said sample, and
(c) detecting an alteration in the level of miR-31 promoter methylation, wherein detection of an alteration in the level of miR-31 promoter methylation indicates the presence of said prostate cancer in said subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein said sample is selected from the group consisting of whole blood, urine, tissue, lymph node or a combination thereof.

### Claim 3 (depends on 1)

The method of claim 1, wherein the level of miR-31 indicates the severity of prostate cancer in said subject.

### Claim 4 (depends on 1)

The method of claim 1, further comprising comparing the level of miR-31 promoter methylation in said sample to that of a sample obtained from benign tissue.

### Claim 5 (depends on 4)

The method of claim 4, wherein the benign tissue is benign prostate tissue.

### Claim 6 (depends on 1)

The method of claim 1, wherein the level of miR-31 promoter methylation is measured by a process selected from, methylation-specific polymerase chain reaction, single-molecule, real-time sequencing, bisulfite DNA sequencing, HPLC, mass spectrometry, microarray or methylated DNA immunoprecipitation.

### Claim 7 (depends on 6)

The method of claim 6, wherein said process is mass spectrometry of bisulfite treated DNA of miR-31.

### Claim 8 (depends on 1)

The method of claim 1, wherein the level of miR-31 promoter methylation is measured by a process comprising polymerase chain reaction in which miR-31 DNA is amplified using PCR primers selected from the group consisting of SEQ ID NOS: 2-9.

### Claim 9

A method of diagnosing prostate cancer in a subject comprising
(a) obtaining a biological sample from said subject, and
(b) measuring the level of expression of miR-31 in said biological sample, wherein the level of miR-31 indicates the presence of prostate cancer in said subject.

### Claim 10 (depends on 9)

The method of claim 9, wherein said biological sample is selected from the group consisting of whole blood, urine, tissue, lymph node or a combination thereof.

### Claim 11 (depends on 9)

The method of claim 9, wherein the level of miR-31 indicates the severity of prostate cancer in said subject.

### Claim 12 (depends on 9)

The method of claim 9, further comprising comparing the level of miR-31 expression in said biological sample to that of a second biological isolated from benign tissue.

### Claim 13 (depends on 12)

The method of claim 12, wherein the benign tissue is benign prostate tissue.

### Claim 14

A method of determining whether a subject is a candidate for treatment of prostate cancer with an AR targeting therapeutic agent comprising
(a) obtaining a biological sample from said subject, and
(b) measuring the level of miR-31 promoter methylation in said biological sample, and
(c) detecting an alteration in the level of miR-31 promoter methylation, wherein the subject is rejected as a candidate if the level of miR-31 promoter methylation is decreased or said subject is selected as a candidate if the level of miR-31 promoter methylation is increased.

### Claim at position 15

15-17. (canceled)

### Claim 18

A method of treating prostate cancer in a subject, comprising administering to the subject an effective amount of an agent that modulates the activity of miR-31.

### Claim at position 17

19-37. (canceled)

### Claim 38

An isolated nucleic acid used for modulating the activity of AR in a cell that is identical to or substantially identical to the nucleotide sequence UCGAUACGGUCGUAGAACGGA [SEQ ID NO:1].
